Reneo Pharmaceuticals CFO Vineet R. Jindal resigns, effective March 31, 2022

OnKure Therapeutics, Inc.

CFO Vineet R. Jindal notified resignation on Jan 28, 2022; effective March 31, 2022.
Separation agreement includes 9 months base salary severance ($385k/year), 12 months COBRA.
Equity vesting accelerated by 12 months; consulting engagement offered post-separation at $375/hour for 12 months.
No replacement CFO named; Jindal to continue service until separation date.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Vineet R. Jindal

Chief Financial Officer

OKUR · OnKure Therapeutics, Inc.

Effective: 2022-03-31
Filed: February 2, 2022, 6:59 PM ET

On January 28, 2022, Vineet R. Jindal notified Reneo Pharmaceuticals, Inc. (the “Company”) of his intention to resign from his position as the Company’s Chief Financial Officer, effective as of March 31, 2022 (the “Separation Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Vineet R. Jindal resigned as Chief Financial Officer at OnKure Therapeutics, Inc..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

On January 28, 2022, Vineet R. Jindal notified Reneo Pharmaceuticals, Inc. (the “Company”) of his intention to resign from his position as the Company’s Chief Financial Officer, effective as of March 31, 2022 (the “Separation Date”).

View on SEC.gov

OnKure Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-025697

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.